Progressive neurodegeneration in aspartylglycosaminuria mice.
Aspartylglycosaminuria (AGU) is one of the most common lysosomal storage disorders in humans. A mouse model for AGU has been recently generated through targeted disruption of the glycosylasparaginase gene, and at a young age the glycosyl asparaginase-deficient mice demonstrated many pathological changes found in human AGU patients (Kaartinen V, Mononen I, Voncken J-W, Gonzalez-Gomez I, Heisterkamp N, Groffen J: A mouse model for aspartylglycosaminuria. Nat Med 1996, 2:1375-1378). Our current findings demonstrate that after the age of 10 months, the general condition of null mutant mice gradually deteriorated. They suffered from a progressive motoric impairment and impaired bladder function and died prematurely. A widespread lysosomal hypertrophy in the central nervous system was detected. This neuronal vacuolation was particularly severe in the lateral thalamic nuclei, medullary reticular nuclei, vestibular nuclei, inferior olivary complex, and deep cerebellar nuclei. The oldest animals (20 months old) displayed a clear neuronal loss and gliosis, particularly in those regions, where the most severe vacuolation was found. The severe ataxic gait of the older mice was likely due to the dramatic loss of Purkinje cells, intensive astrogliosis and vacuolation of neurons in the deep cerebellar nuclei, and the severe vacuolation of the cells in vestibular and cochlear nuclei. The impaired bladder function and subsequent hydronephrosis were secondary to involvement of the central nervous system. These findings demonstrate that the glycosylasparaginase-deficient mice share many neuropathological features with human AGU patients, providing a suitable animal model to test therapeutic strategies in the treatment of the central nervous system effects in AGU.
Gonzalez-Gomez
I
I
Department of Pathology, Childrens Hospital Los Angeles Research Institute and University of Southern California, School of Medicine, USA.
Mononen
I
I
Heisterkamp
N
N
Groffen
J
J
Kaartinen
V
V
D000117:Acetylglucosamine / Q000652:urine*; D000818:Animals; D054880:Aspartylglucosaminuria; D001227:Aspartylglucosylaminase / Q000235:genetics; D002490:Central Nervous System / Q000378:metabolism / Q000473:pathology; D003593:Cytoplasm / Q000473:pathology; D005260:Female; D005684:Gait / Q000502:physiology; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D007124:Immunoenzyme Techniques; D016464:Lysosomal Storage Diseases / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D008247:Lysosomes / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D019636:Neurodegenerative Diseases / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D009474:Neurons / Q000473:pathology; D001743:Urinary Bladder / Q000294:innervation / Q000473:pathology; D014617:Vacuoles / Q000473:pathology
D005904:Glial Fibrillary Acidic Protein; D001227:Aspartylglucosylaminase; D000117:Acetylglucosamine